Advair Generic Looms, But GSK Says Growth Will Return Regardless
This article was originally published in The Pink Sheet Daily
CEO Andrew Witty reconfirmed that GSK’s respiratory business will return to growth in 2016 and said the company’s five-year outlook does not depend on the timing of a generic Advair. Mylan recently filed what is believed to be the first ANDA for a generic Advair Diskus in the US.
Register for our free email digests: